Jornal Vascular Brasileiro
https://www.jvascbras.org/article/doi/10.1590/jvb.2014.025
Jornal Vascular Brasileiro
Review Article

Off-label prescriptions in diabetic foot

Prescrições off-label em pé diabético

Luís Jesuíno de Oliveira Andrade; Larissa Santos França; Paulo Roberto Santana de Melo; Marcelo Araújo

Downloads: 1
Views: 724

Abstract

Prescription of a drug outside of the indications for which it was originally approved by regulators is internationally known as "off-label" prescription. We describe off-label treatments for the diabetic foot reported in international scientific literature. This is a qualitative and descriptive bibliographical review based on the results of a search of the Medline international database. The criteria for review were publication between January 1985 and November 2013, and the MeSH (Medical Subject Heading) keywords "off-label use" OR "off-label" OR "off-label prescribing" plus "diabetic foot" were input on the search form. Nine studies were selected that contained information about off-label treatments for the diabetic foot. We conclude that the practice of off-label prescribing has potential benefits. In some situations an off-label prescription is the only treatment available for patients, either because a more targeted drug does not exist, or because other methods of treatment are ineffective or unavailable due to patient intolerance.

Keywords

off-label use, diabetic foot, diabetes mellitus

Resumo

A prescrição de um medicamento sem as indicações para as quais a droga foi originalmente aprovada por órgãos reguladores é internacionalmente conhecida como prescrição off-label. Descrevemos a terapia off-label em pé diabético, relatada na literatura científica internacional, por meio de uma revisão bibliográfica qualitativa, descritiva, através de pesquisa na base de dados internacional Medline, para seleção dos artigos. Os critérios para revisão foram publicações entre janeiro de 1985 e novembro de 2013, sendo as palavras-chave MeSH "off-label use" OR "off-label" OR "off-label prescribing" plus "diabetic foot" – colocadas no formulário de busca. Foram selecionados nove artigos com informações sobre a terapia off-labelem pé diabético. Conclui-se que a prática de prescrição off-labelpossui benefícios potenciais em muitas situações. Em algumas circunstâncias, uma prescrição off-label é o único tratamento disponível, seja por não existir uma droga específica, seja porque outros métodos de tratamento são ineficazes ou não disponíveis por intolerância.

Palavras-chave

uso off-label, pé diabético, diabetes mellitus

References

Emmerich J, Dumarcet N, Lorence A. France's new framework for regulating off-label drug use. N Engl J Med. 2012;367(14):1279-81.

Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358(14):1427-9.

Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8.

Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc. 2012;87(10):982-90.

Griffis CD, Metcalfe S, Bowling FL, Boulton AJ, Armstrong DG. The use of gentamycin-impregnated foam in the management of diabetic foot infections: a promising delivery system?. Expert Opin Drug Deliv. 2009;6(6):639-42.

Nelson EA, O'Meara S, Golder S, Dalton J, Craig D, Iglesias C. Systematic review of antimicrobial treatments for diabetic foot ulcers. Diabet Med. 2006;23(4):348-59.

Lipsky BA, Kuss M, Edmonds M, Reyzelman A, Sigal F. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc. 2012;102(3):223-32.

Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005;366(9498):1725-35.

Lo Pardo D, Pezzuti G, Selleri C, Pepe S, Esposito S. Adjuvant treatment of diabetic foot. Infez Med. 2012;20(^sSuppl 1):35-41.

Holmes C, Wrobel JS, Maceachern MP, Boles BR. Collagenbased wound dressings for the treatment of diabetes-related foot ulcers: a systematic review. Diabetes Metab Syndr Obes. 2013;6:17-29.

Papanas N, Maltezos E. Cilostazol in diabetic neuropathy: premature farewell or new beginning?. Angiology. 2011;62(8):605-8.

Solerte SB, Fioravanti M, Cerutti N. Retrospective analysis of long-term hemorheologic effects of pentoxifylline in diabetic patients with angiopathic complications. Acta Diabetol. 1997;34(2):67-74.

Cicco G, Giorgino F, Cicco S. Wound healing in diabetes: hemorheological and microcirculatory aspects. Adv Exp Med Biol. 2011;701:263-9.

Baldwin DS, Kosky N. Off-label prescribing in psychiatric practice. Adv Psychiatr Treat. 2007;13(6):414-22.

Lowe-Ponsford FL, Baldwin DS. Off-label prescribing by psychiatrists. Psychiatr Bull. 2000;24(11):415-7.

Gazarian M, Kelly M, McPhee JR, Graudins LV, Ward RL, Campbell TJ. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185(10):544-8.

Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-6.

Resolução RDC n° 47, de 08 de setembro de 2009. 2009:31.

Blanes JI. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter. 2011;24(4):233-62.

Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719-24.

Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)"> Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV)">
5ddd809c0e88250e361da3ea jvb Articles

J Vasc Bras

Share this page
Page Sections